Memorial Sloan Kettering Cancer Center

Quick facts

Marketed products

• Azacitidine (AZA) · Oncology
  Azacitidine inhibits DNA methyltransferase, leading to DNA demethylation and reactivation of silenced tumor suppressor genes.
• DANYELZA · Oncology
  DANYELZA is a monoclonal antibody that targets GD2, a glycolipid antigen expressed on neuroblastoma cells, enabling immune-mediated tumor cell destruction.
• Daratumumab Hyaluronidase-fihj · Oncology
  Daratumumab binds to CD38 on multiple myeloma cells to trigger their destruction, while hyaluronidase enables faster subcutaneous administration by breaking down hyaluronic acid in tissue.
• GnRH agonist/antagonist · Oncology
  GnRH agonists/antagonists suppress gonadotropin-releasing hormone signaling to reduce sex hormone production, used in oncology to manage hormone-sensitive cancers and their treatment side effects.
• LAR Lanreotide · Oncology
  Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.
• Maitake · Other
• Meclofenamate · Immunology
• Oxaliplatin (OXAL) · Oncology
  Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.
• PECS-1 · Other
• Pembrolizuma · Oncology
• Revaree Plus
• Serratus · Other
• therapeutic testosterone · Endocrinology / Oncology
  Therapeutic testosterone replaces or supplements endogenous testosterone to restore normal hormonal levels and physiological function.
• Trastuzumab deruxtecan-nxki · Oncology
  Trastuzumab deruxtecan-nxki is an antibody-drug conjugate that binds HER2-positive cancer cells and delivers a topoisomerase I inhibitor payload to kill them.
• Vancomycin and Gentamicin · Infectious Disease
  Vancomycin and gentamicin are a combination antibiotic regimen that inhibits bacterial cell wall synthesis and protein synthesis to treat serious infections.

Phase 3 pipeline

• anti-thymocyte globulin (ATG) · Immunology
  Anti-thymocyte globulin (ATG) works by binding to and depleting T-lymphocytes, which are a type of immune cell.
• Bacillus Calmette-Guérin (BCG) · Oncology
  BCG is a live attenuated mycobacterial vaccine that stimulates the immune system to recognize and destroy cancer cells, particularly in the bladder.
• CAR T cells · Oncology
  CAR T cells are engineered immune cells that recognize and kill cancer cells by expressing chimeric antigen receptors targeting tumor-associated antigens.
• Empirical Vancomycin · Infectious Disease / Oncology (supportive care in cancer patients)
  Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.
• Hemostatic Agent · Hematology / Surgery / Oncology
  A hemostatic agent promotes blood clotting and stops bleeding by enhancing coagulation cascade activation or platelet function.
• Mitomycin C (MMC) · Oncology
  Mitomycin C is an alkylating agent that cross-links DNA strands, preventing cell division and triggering cancer cell death.
• Pembrolizumab (MK-3475) · Oncology
  Pembrolizumab is a monoclonal antibody that blocks PD-1 on T cells, allowing the immune system to recognize and attack cancer cells.
• peripheral blood stem cell transplantation · Oncology
  Peripheral blood stem cell transplantation involves the transfer of stem cells from the blood into the body to help the bone marrow recover after chemotherapy or radiation.
• placebo tablets and questionaires · Psychiatry
  This drug is a placebo, having no active pharmacological mechanism.
• Prophylactic Vancomycin · Oncology / Infectious Disease Prevention
  Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.
• Propofol+ Rocuronium+ Fentanyl + Inhalational · Anesthesiology
  This is a combination anesthetic regimen that induces unconsciousness, provides muscle paralysis, and delivers pain relief for surgical procedures.
• sildenafil citrate and questionaires
• Systemic Therapy/Standard of Care · Oncology
  This drug targets the PD-1 receptor to inhibit cancer cell growth.
• Topical Dapsone 5% Gel · Dermatology
  Topical dapsone reduces inflammation and bacterial colonization in skin lesions through its antimicrobial and anti-inflammatory properties.

Phase 2 pipeline

• HIPEC with Mitomycin-C
• pilimumab · Other
• Xevinapan · Other

Phase 1 pipeline

• 131I-MIP-1095
• Atezolizumb · Other
• cisplatin or carboplatin-based
• concurrent capecitabine or 5-FU
• Drug Eluting Bead Transarterial Chemoembolization
• Embospheres · Other
• HER2 directed therapy
• Infusion of MCARH109 T cells
• M28z1XXPD1DNR CAR
• MUC-2-KLH vaccine
• oral β-glucan
• recombinant 70-kD heat-shock protein
• Trametinib 1.5 MG

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Memorial Sloan Kettering Cancer Center portfolio CI brief
• Memorial Sloan Kettering Cancer Center pipeline updates RSS